QuidelOrtho (QDEL) investor relations material

Organizational transformation and cost management

• Over 900 positions eliminated and $140 million in cost savings achieved, with an additional $30–$40 million targeted for this year.

• Leadership team revamped across HR, R&D, quality, regulatory, operations, and commercial functions.

• Further targeted staffing reductions and procurement projects planned to improve margins by about 100 basis points year-over-year.

• Donor screening business being unwound, contributing to margin expansion in the back half of the year.

• Focus on sustainable working capital and CapEx improvements to support long-term free cash flow.

Market dynamics and regional performance

• Respiratory business expected to be down 8% for the year, but underlying demand and protocols remain stable.

• China facing a 30–40% pricing impact from broad-based reimbursement changes, with a $30 million headwind expected in 2026 and low growth anticipated in the second half.

• Middle East orders delayed due to shipping and tender uncertainties, but recovery expected in the second half of the year.

• Labs and immunohematology businesses show stable mid-single-digit growth, with strong contracts and high retention rates.

• LATAM and Asia Pacific (excluding China) identified as under-penetrated growth opportunities.

Growth drivers and product innovation

• Launches of VITROS 450 and ECL analyzers outside the U.S. target low-cost markets and expand addressable market.

• High-sensitivity troponin launch in the U.S. gaining traction, with several hundred customers converted.

• NULEXA (formerly LEX) molecular platform expected to place a few hundred units in the back half of the year, with broader commercialization and menu expansion planned for 2027–2028.

• Menu build-out for NULEXA to include Strep A and RSV assays, with the Flu SARS combo as the initial workhorse.

• Focus on leveraging large installed base (SOFIA, Triage, NULEXA) and expanding non-respiratory assay offerings.